About Myostatin Propeptide
Endogenous N-terminal fragment of myostatin precursor; binds and neutralizes mature myostatin (GDF-8); naturally produced to regulate the extent of muscle inhibition
Myostatin propeptide is the endogenous N-terminal prodomain of the precursor myostatin protein (GDF-8) that, following cleavage of the mature myostatin dimer, remains non-covalently associated with it as a latency-associated complex, maintaining the active growth factor in an inactive state until proteolytic activation by BMP-1/tolloid family metalloproteinases releases it to engage ActRIIB receptors and signal through the Smad2/3 pathway. Recombinant versions of the propeptide can act as endogenous-mechanism inhibitors of myostatin by sequestering the mature peptide in an inactive complex, reducing the inhibitory signaling that myostatin exerts on skeletal muscle protein synthesis and satellite cell activity in the ActRII/Smad pathway. Foundational rodent studies demonstrate that overexpression of the myostatin propeptide produces significant skeletal muscle hypertrophy, and the BMP-1/tolloid proteolytic activation mechanism of the propeptide-myostatin latent complex has been characterized genetically in mouse models. Myostatin propeptide is a research compound with no regulatory approval in any jurisdiction; recombinant propeptide administration has not been evaluated in human clinical trials for muscle building or performance applications, and no human safety or pharmacokinetic data has been established.
Myostatin Propeptide Benefits & Research Areas
Research Signals
Commonly researched in the context of
Population research notes
These signals reflect research interest areas, not treatment indications.
Regulatory & Evidence
Risk Profile
Moderate risk profile in research contexts. Review contraindications and administration guidelines before use.
Regulatory Status
- Availability Status
- Research Only
- FDA Status
- Not Evaluated
N-terminal propeptide of myostatin that inhibits myostatin signalling. No FDA approval, no NDA or IND. Research tool compound. Not on any FDA list. No active clinical development program.
Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
Research Sources
2 sources cited · 2 moderate
2 Animals
Activation of latent myostatin by the BMP-1/tolloid family of metalloproteinases
Proceedings of the National Academy of Sciences · 2004
Research in animal models found that BMP-1/tolloid metalloproteinases cleave the myostatin propeptide to activate latent myostatin, and that a protease-resistant mutant propeptide injected into adult mice caused significant increases in skeletal muscle mass, suggesting that myostatin propeptide stability is a key determinant of muscle growth regulation.
Regulation of myostatin activity and muscle growth
Proceedings of the National Academy of Sciences · 2001
Research in transgenic mice demonstrated that overexpression of the myostatin propeptide, follistatin, or a dominant-negative activin receptor IIB each produced dramatic increases in skeletal muscle mass comparable to myostatin knockout, identifying the propeptide as an endogenous myostatin inhibitor and a candidate molecule for promoting muscle growth.
Myostatin Propeptide Side Effects & Safety Considerations
Moderate risk profile. Review all reported considerations carefully before use.
Reported contraindications & considerations
Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.
Where to Buy Myostatin Propeptide — Providers & Availability
1 providerClinics
1 providerStay updated on verified Myostatin Propeptide providers
New verified providers added weekly — delivered to your inbox.
Questions to Ask Your Provider
Frequently Asked Questions — Myostatin Propeptide
Myostatin propeptide is the endogenous N-terminal prodomain of the precursor myostatin protein (GDF-8) that, following cleavage of the mature myostatin dimer, remains non-covalently associated with it as a latency-associated complex, maintaining the active growth factor in an inactive state until proteolytic activation by BMP-1/tolloid family metalloproteinases releases it to engage ActRIIB receptors and signal through the Smad2/3 pathway. Recombinant versions of the propeptide can act as endogenous-mechanism inhibitors of myostatin by sequestering the mature peptide in an inactive complex, reducing the inhibitory signaling that myostatin exerts on skeletal muscle protein synthesis and satellite cell activity in the ActRII/Smad pathway.
myostatin inhibition, muscle hypertrophy, strength gain, lean mass increase.
Research on Myostatin Propeptide primarily documents effects related to myostatin inhibition and muscle hypertrophy and strength gain and lean mass increase. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.
Reported contraindications and considerations for Myostatin Propeptide include active cancer, prostate conditions, pregnancy. This is educational information only — consult a qualified healthcare professional before use.
1 provider in the directory currently offers Myostatin Propeptide.
Research in animal models found that BMP-1/tolloid metalloproteinases cleave the myostatin propeptide to activate latent myostatin, and that a protease-resistant mutant propeptide injected into adult mice caused significant increases in skeletal muscle mass, suggesting that myostatin propeptide stability is a key determinant of muscle growth regulation.